newsfilter
← Latest News
GlobeNewswire·

INVO Fertility Announces Patent Issuance for Modified INVOcell® Device

  • INVO Fertility, Inc. announced the final issuance of U.S. Patent No. 12,544,204 B2 for a modified version of its INVOcell device on February 10, 2026.
  • The patent provides intellectual property protection for the INVOcell device through 2040.
  • The modified design features a single main chamber without a separate microchamber, differing from the original design that included both chambers.
  • INVOcell is the world's first FDA-cleared intravaginal culture (IVC) system, originally cleared in 2015, with a 2023 update extending the incubation period from three to five days.
  • The simplified design was developed based on real-world clinical use and practitioner feedback before being submitted for patent protection.
  • CEO Steve Shum stated the patent issuance strengthens the company's intellectual property foundation while supporting its growth strategy to offer patient-centered fertility care.
  • INVO Fertility currently operates two INVO Centers and one IVF clinic in the United States while also selling and distributing INVOcell to third-party clinics.